Amendment: Neuronetics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

2/6/25 4:21:30 PM ET

$STIM

Medical/Dental Instruments

Health Care

Get the next $STIM alert in real time by email

8-K/A

UNITED STATES

SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 10, 2024

NEURONETICS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-38546	33-1051425
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)


3222 Phoenixville Pike, Malvern, PA		19355
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (610) 640-4202

(Former name or former address, if changed since last report.) Not applicable.

Check the appropriate box below if the

Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol (s)	Name on each exchange on which registered
Common Stock ($0.01 par value)	STIM	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or

Rule 12b-2

of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange

Act. ☐

Table of Contents

Explanatory Note

As previously disclosed in the Current Reports on Form

8-K

filed by Neuronetics, Inc. (the “Company”) with the Securities and Exchange Commission (the “SEC”), the Company entered into an arrangement agreement on August 11, 2024 with Greenbrook TMS Inc. (“Greenbrook”), pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Greenbrook pursuant to a plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). The Arrangement was effective as of December 9, 2024.

This Amendment No. 1 on Form

8-K/A

is being filed to amend Item 9.01(a) and (b) of the Current Report on Form

8-K

that the Company filed with the SEC on December 10, 2024, regarding the completion of its acquisition of Greenbrook to include the historical financial statements of Greenbrook required by Item 9.01(a) of Form

8-K

and the pro forma financial information required by Item 9.01(b) of Form

8-K.

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired

The audited financial statements of Greenbrook as of and for the years ended December 31, 2022 and December 31, 2023, together with the notes related thereto and the Report of Independent Registered Public Accounting Firm thereon, are filed as Exhibit 99.1 to this Form

8-K/A

and incorporated by reference herein.

The unaudited financial statements of Greenbrook as of and for the nine months ended November 30, 2024 are filed as Exhibit 99.2 to this Form

8-K/A

and incorporated by reference herein.

(b) Pro Forma Financial Information

The unaudited pro forma financial information for the Company, after giving effect to the acquisition of Greenbrook and

adjustments

described in such pro forma financial information, is attached hereto as Exhibit 99.3 to this Form

8-K/A

and incorporated by reference

herein

(d) Exhibits


Exhibit Number		Description

23.1		Consent of Independent Registered Accounting Firm, KPMG LLP

99.1		Audited consolidated financial statements of Greenbrook as of and for the years ended December 31, 2022 and December 31, 2023 and the notes related thereto and Report of Independent Registered Public Accounting Firm thereon (incorporated by reference to pages F-1 through F-55 of Greenbrook’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (SEC file No. 001-40199), filed with the SEC on April 26, 2024).

99.2		Unaudited consolidated condensed financial statements of Greenbrook as of September 30, 2024 and for the periods ended September 30, 2024 and the notes related thereto.

99.3		Unaudited pro forma combined balance sheet as of September 30, 2024 and the unaudited pro forma combined statement of operations for the periods ended September 30, 2024 and the year ended December 31, 2023, giving effect to the acquisition of Greenbrook.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document )

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this

report

to be signed on its behalf by the undersigned hereunto duly authorized.


	NEURONETICS, INC.
	(Registrant)

Date: February 6, 2025	By:	/s/ Stephen Furlong
	Name:	Stephen Furlong
	Title:	EVP, Chief Financial Officer and Treasurer

Get the next $STIM alert in real time by email

Date

Price Target

Rating

Analyst

8/13/2024

Outperform → Mkt Perform

William Blair

10/14/2021

$18.00 → $12.00

Market Outperform

JMP Securities

10/13/2021

Outperform → Mkt Perform

William Blair

10/13/2021

Buy → Neutral

BTIG

Amendment: Neuronetics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

Chat with this insight

Recent Analyst Ratings for $STIM

$STIM Press Releases

Fastest customizable press release news feed in the world

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

$STIM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, GC, CCO and CS Macan William Andrew sold $77,946 worth of shares (18,965 units at $4.11), decreasing direct ownership by 5% to 369,682 units (SEC Form 4)

EVP, CFO and Treasurer Furlong Stephen sold $71,132 worth of shares (17,307 units at $4.11), decreasing direct ownership by 4% to 454,420 units (SEC Form 4)

EVP, CFO and Treasurer Furlong Stephen sold $41,536 worth of shares (10,845 units at $3.83), decreasing direct ownership by 2% to 471,727 units (SEC Form 4)

$STIM Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

$STIM Financials

Live finance-specific insights

CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

Neuronetics to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call

$STIM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Neuronetics downgraded by William Blair

JMP Securities reiterated coverage on Neuronetics with a new price target

Neuronetics downgraded by William Blair

$STIM SEC Filings

SEC Form 144 filed by Neuronetics Inc.

SEC Form 424B5 filed by Neuronetics Inc.

SEC Form 424B5 filed by Neuronetics Inc.

$STIM Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D filed by Neuronetics Inc.

Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

$STIM Leadership Updates

Live Leadership Updates

Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

Recent Analyst Ratings for
$STIM

$STIM
Press Releases

$STIM
Insider Trading

$STIM
Insider Purchases

$STIM
Financials

$STIM
Analyst Ratings

$STIM
SEC Filings

$STIM
Large Ownership Changes

$STIM
Leadership Updates